Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11851
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
| $49K | ﹤0.01% |
26,100
+6,100
| +31% | +$11.6K |
|
|
NCTY
11852
CALL
The9 Ltd
NCTY
$70M
| $49K | ﹤0.01% |
2,910
+1,150
| +65% | +$22.8K |
|
|
RGLS
11853
DELISTED
Regulus Therapeutics
RGLS
| $49K | ﹤0.01% |
+23,655
| New | +$57.4K |
|
11854
Savara
SVRA
$1.11B
| $49K | ﹤0.01% |
32,523
+19,952
| +159% | +$26.2K |
|
|
XNET
11855
Xunlei
XNET
$334M
| $49K | ﹤0.01% |
30,791
-35,683
| -54% | -$50.7K |
|
|
AIOT
11856
PowerFleet Inc
AIOT
$417M
| $49K | ﹤0.01% |
22,540
-1,551
| -6% | -$3.94K |
|
|
ARTEW
11857
DELISTED
Artemis Strategic Investment Corporation Warrant
ARTEW
| $49K | ﹤0.01% |
544,651
-1,330
| -0.2% | -$248 |
|
|
VLTA
11858
PUT
DELISTED
Volta Inc.
VLTA
| $49K | ﹤0.01% |
38,000
-67,000
| -64% | -$149K |
|
11859
CALL
Gerdau
GGB
$9.3B
| $48K | ﹤0.01% |
13,986
-24,696
| -64% | -$110K |
|
11860
CALL
Humacyte
HUMA
$168M
| $48K | ﹤0.01% |
15,000
-15,900
| -51% | -$88.4K |
|
11861
Marker Therapeutics
MRKR
$19M
| $48K | ﹤0.01% |
+14,432
| New | +$48K |
|
11862
PUT
PAVmed
PAVM
$37.2M
| $48K | ﹤0.01% |
114
-84
| -42% | -$40.6K |
|
11863
CALL
Pluri
PLUR
$17.3M
| $48K | ﹤0.01% |
4,925
-138
| -3% | -$1.7K |
|
|
GGRP
11864
CALL
Glimpse Group
GGRP
$19.6M
| $48K | ﹤0.01% |
+12,000
| New | +$52.8K |
|
|
TRONW
11865
DELISTED
Corner Growth Acquisition Corp. 2 Warrants
TRONW
| $48K | ﹤0.01% |
400,099
-231
| -0.1% | -$26 |
|
|
TTOO
11866
DELISTED
T2 Biosystems, Inc
TTOO
| $48K | ﹤0.01% |
59
-12
| -17% | -$17.8K |
|
|
ENERR
11867
DELISTED
Accretion Acquisition Corp Right
ENERR
| $48K | ﹤0.01% |
400,070
+70
| +0% | +$11 |
|
11868
CALL
StealthGas
GASS
$352M
| $47K | ﹤0.01% |
14,600
-35,800
| -71% | -$99.9K |
|
11869
LifeMD
LFMD
$166M
| $47K | ﹤0.01% |
23,400
-89,136
| -79% | -$221K |
|
11870
CALL
Mustang Bio
MBIO
$4.5M
| $47K | ﹤0.01% |
108
+18
| +20% | +$9.96K |
|
11871
Prenetics Global
PRE
$331M
| $47K | ﹤0.01% |
+783
| New | +$55.9K |
|
11872
CALL
RAVE Restaurant Group
RAVE
$43.2M
| $47K | ﹤0.01% |
43,500
+20,300
| +88% | +$20.1K |
|
11873
ZK International Group
ZKIN
$60.8M
| $47K | ﹤0.01% |
6,466
+3,890
| +151% | +$31.3K |
|
|
PCTI
11874
DELISTED
PCTEL, Inc. Common Stock
PCTI
| $47K | ﹤0.01% |
+11,533
| New | +$48.8K |
|
|
KBNT
11875
DELISTED
Kubient, Inc. Common Stock
KBNT
| $47K | ﹤0.01% |
+72,236
| New | +$75.6K |
|
Similar funds
Citadel Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
- Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.